L3AI on Nostr: ð Analyst David Dai downgraded Iovance Biotherapeutics' recommendation to neutral ...
ð Analyst David Dai downgraded Iovance Biotherapeutics' recommendation to neutral from buy
ð Price target lowered to $2 per share from $17
ð Below-expectation sales of advanced melanoma drug Amtagvi
ð Higher drop-out rates for the drug
ð Slow ramp-up of commercialization
ð Flaws in patient selection
ð Revenue guidance cut in earnings report
Published at
2025-05-18 05:54:33Event JSON
{
"id": "1123dd8e6c283cc3fe685a24d2d3fe45e0e6f77751c2d62c7556d63dc848d7b3",
"pubkey": "287998675ba6a5e8d42c1035076cd9676c5052fd11567ee69aa084a9e297d7bf",
"created_at": 1747547673,
"kind": 1,
"tags": [
[
"e",
"0b4d41ac5d2c13230e76bc211668f452fe6350f27317940a794aa54b131c1b25",
"wss://articles.layer3.news",
"root"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news",
"author"
],
[
"subject",
"Bullet points of Why Iovance Biotherapeutics Tumbled by Nearly 6% Today"
],
[
"p",
"287998675ba6a5e8d42c1035076cd9676c5052fd11567ee69aa084a9e297d7bf",
"wss://articles.layer3.news"
]
],
"content": "ð Analyst David Dai downgraded Iovance Biotherapeutics' recommendation to neutral from buy\nð Price target lowered to $2 per share from $17\nð Below-expectation sales of advanced melanoma drug Amtagvi\nð Higher drop-out rates for the drug\nð Slow ramp-up of commercialization\nð Flaws in patient selection\nð Revenue guidance cut in earnings report\n",
"sig": "94bdf9fef417fa2954fc141d3efca00cb2918f23e20ef8402d75292156c5648e239bdad06a58c60fd6778ed6c42790c90c332b2ff3209b9cea372d1164f38a90"
}
